Caffeine as a lead compound for the design of therapeutic agents for the treatment of parkinson's disease

Current Medicinal Chemistry

Volumn 22, Issue 8, 2015, Pages 975-988

  Petzer, Jacobus P ^a   Petzer, Anél ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Adenosine A2A receptor; Caffeine; Drug design; Dual target directed; Inhibition; Monoamine oxidase; Parkinson's disease

Indexed keywords

8 BENZYLOXYCAFFEINE DERIVATIVE; 8 STYRYLCAFFEINE DERIVATIVE; ADENOSINE A2 RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); AMINOCAFFEINE DERIVATIVE; CAFFEINE DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; THIOCAFFEINE DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; MONOAMINE OXIDASE INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; MOLECULAR DOCKING; PARKINSON DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; HUMAN; METABOLISM;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CAFFEINE; DRUG DESIGN; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 84931281540     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666141215160015     Document Type: Article

References (86)

1. Olanow. C. W.; Stern, M. B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 2009, 72(21 Suppl 4), S1-136.
2. Carlsson, A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J. Neural Transm., 2002, 109(5-6), 777-787.
3. Pedrosa, D. J.; Timmermann, L. Review: management of Parkinson's disease. Neuropsychiatr. Dis. Treat., 2013, 9, 321-340.
4. Talati, R.; Baker, W. L.; Patel, A. A.; Reinhart, K.; Coleman, C. I. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: A meta analysis. Int. J. Clin. Pract., 2009, 63(4), 613-623.
5. Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Lang, A.; Olanow, C. W.; Tanner, C.; Marek, K. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 2004, 351(24), 2498-2508.
6. Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2005, 105(3), 267-310.
7. Schwarzschild, M. A.; Agnati, L.; Fuxe, K.; Chen, J. F.; Morelli, M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci., 2006, 29(11), 647-654.
8. Bara-Jimenez, W.; Sherzai, A.; Dimitrova, T.; Favit, A.; Bibbiani, F.; Gillespie, M.; Morris, M. J.; Mouradian, M. M.; Chase, T. N. Adenosine A2A receptor antagonist treatment of Parkinson's disease. Neurology, 2003, 61(3), 293-296.
9. Youdim, M. B.; Edmondson, D.; Tipton, K. F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7(4), 295-309.
10. Youdim, M. B.; Bakhle, Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol., 2006, 147(Suppl 1), S287-296.
11. Fredholm, B. B.; Bättig, K.; Holmén, J.; Nehlig, A.; Zvartau, E. E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev., 1999, 51(1), 83-133.
12. Jacobson, K. A.; Gallo-Rodriguez, C.; Melman, N.; Fischer, B.; Maillard, M.; van Bergen, A.; van Galen, P. J.; Karton, Y. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J. Med. Chem., 1993, 36(10), 1333-1342.
13. Müller, C. E.; Geis, U.; Hipp, J.; Schobert, U.; Frobenius, W.; Pawowski, M.; Suzuki, F.; Sandoval-Ramírez, J. Synthesis and structure-activity relationships of 3, 7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. J. Med. Chem., 1997, 40(26), 4396-4405.
14. Petzer, J. P.; Steyn, S.; Castagnoli, K. P.; Chen, J. F.; Schwarzschild, M. A.; Van der Schyf, C. J.; Castagnoli, N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg. Med. Chem., 2003, 11(7), 1299-1310.
15. Daly, J. W. Caffeine analogs: biomedical impact. Cell Mol. Life Sci., 2007, 64(16), 2153-2169.
16. Müller, C. E.; Jacobson, K. A. Xanthines as adenosine receptor antagonists. Handb. Exp. Pharmacol., 2011, 200, 151-199.
17. Ribeiro, J. A.; Sebastião, A. M.; Caffeine and adenosine. J. Alzheimers Dis., 2010, 20(Suppl 1), S3-15.
18. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. Nomenclature and classification of purinoceptors. Pharmacol. Rev., 1994, 46(2), 143-156.
19. Petzer, A.; Pienaar, A.; Petzer, J. P. The interactions of caffeine with monoamine oxidase. Life Sci., 2013, 93(7), 283-287.
20. Garrett, B. E.; Holtzman, S. G. Does adenosine receptor blockade mediate caffeine-induced rotational behavior? J. Pharmacol. Exp. Ther., 1995, 274(1), 207-214.
21. Smellie, F. W.; Davis, C. W.; Daly, J. W.; Wells, J. N. Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity. Life Sci., 1979, 24(26), 2475-2482.
22. McPherson, P. S.; Kim, Y. K.; Valdivia, H.; Knudson, C. M.; Takekura, H.; Franzini-Armstrong, C.; Coronado, R.; Campbell, K. P. The brain ryanodine receptor: A caffeine-sensitive calcium release channel. Neuron, 1991, 7(1), 17-25.
23. Fredholm, B. B.; Hedqvist, P.; Vernet, L. Effect of theophylline and other drugs on rabbit renal cyclic nucleotide phosphodiesterase, 5'-nucleotidase and adenosine deaminase. Biochem. Pharmacol., 1978, 27(24), 2845-2850.
24. Fredholm, B. B.; Lindgren, E. Inhibition of soluble 5'-nucleotidase from rat brain by different xanthine derivatives. Biochem. Pharmacol., 1983, 32(18), 2832-2834.
25. Shi, D.; Padgett, W. L.; Daly, J. W. Caffeine analogs: effects on ryanodine-sensitive calcium-release channels and GABAA receptors. Cell Mol. Neurobiol., 2003, 23(3), 331-347.
26. Van der Walt, M. M.; Terre'Blanche, G.; Petzer, A.; Lourens, A. C.; Petzer, J. P. The adenosine A2A antagonistic properties of selected C8-substituted xanthines. Bioorg. Chem., 2013, 49, 49-58.
27. Chen, J. F.; Steyn, S.; Staal, R.; Petzer, J. P.; Xu, K.; Van Der Schyf, C. J.; Castagnoli, K.; Sonsalla, P. K.; Castagnoli, N. Jr.; Schwarzschild, M. A. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J. Biol. Chem., 2002, 277(39), 36040-36044.
28. Pretorius, J.; Malan, S. F.; Castagnoli, N. Jr.; Bergh, J. J.; Petzer, J. P. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E, E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg. Med. Chem., 2008, 16(18), 8676-8684.
29. Ross, G. W.; Abbott, R. D.; Petrovitch, H.; Morens, D. M.; Grandinetti, A.; Tung, K. H.; Tanner, C. M.; Masaki, K. H.; Blanchette, P. L.; Curb, J. D.; Popper, J. S.; White, L. R. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA., 2000, 283(20), 2674-2679.
30. Ascherio, A.; Zhang, S. M.; Hernán, M. A.; Kawachi, I.; Colditz, G. A.; Speizer, F. E.; Willett, W. C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol., 2001, 50(1), 56-63.
31. Chen, J. F.; Xu, K.; Petzer, J. P.; Staal, R.; Xu, Y. H.; Beilstein, M.; Sonsalla, P. K.; Castagnoli, K.; Castagnoli, N. Jr.; Schwarzschild, M. A. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 2001, 21(10), RC143.
32. Ikeda, K.; Kurokawa, M.; Aoyama, S.; Kuwana, Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem., 2002, 80(2), 262-270.
33. Shih, J. C.; Chen, K.; Ridd, M. J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci., 1999, 22, 197-217.
34. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubálek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem., 2004, 11(15), 1983-1993.
35. Westlund, K. N.; Denney, R. M.; Kochersperger, L. M.; Rose, R. M.; Abell, C. W. Distinct monoamine oxidase A and B populations in primate brain. Science, 1985, 230(4722), 181-183.
36. Fowler, C. J.; Wiberg, A.; Oreland, L.; Marcusson, J.; Winblad, B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J. Neural Transm., 1980, 49(1-2), 1-20.
37. Kalaria, R. N.; Mitchell, M. J.; Harik, S. I. Monoamine oxidases of the human brain and liver. Brain, 1988, 111(Pt 6), 1441-1451.
38. Riachi, N. J.; Harik, S. I. Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys. Exp. Neurol., 1992, 115(2), 212-217.
39. Collins, G. G.; Sandler, M.; Williams, E. D.; Youdim, M. B. Multiple forms of human brain mitochondrial monoamine oxidase. Nature, 1970, 225(5235), 817-820.
40. Fowler, J. S.; Volkow, N. D.; Wang, G. J.; Logan, J.; Pappas, N.; Shea, C.; MacGregor, R. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging, 1997, 18(4), 431-435.
41. Levitt, P.; Pintar, J. E.; Breakefield, X. O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. U. S. A., 1982, 79(20), 6385-6389.
42. Deftereos, S. N.; Dodou, E.; Andronis, C.; Persidis, A. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. Expert Rev. Clin. Pharmacol., 2012, 5(4), 413-425.
43. Fernandez, H. H.; Chen, J. J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, 2007, 27(12 Pt 2), 174S-185S.
44. Finberg, J. P.; Wang, J.; Bankiewicz, K.; Harvey-White, J.; Kopin, I. J.; Goldstein, D. S. Increased striatal dopamine production from LDOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J. Neural Transm. Suppl., 1998, 52, 279-285.
45. Shoulson, I.; Oakes, D.; Fahn, S.; Lang, A.; Langston, J. W.; LeWitt, P.; Olanow, C. W.; Penney, J. B.; Tanner, C.; Kieburtz, K.; Rudolph, A. Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol., 2002, 51(5), 604-612.
46. Pålhagen, S.; Heinonen, E. H.; Hägglund, J.; Kaugesaar, T.; Kontants, H.; Mäki-Ikola, O.; Palm, R.; Turunen, J. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology, 1998, 51(2), 520-525.
47. Gesi, M.; Santinami, A.; Ruffoli, R.; Conti, G.; Fornai, F. Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). Pharmacol. Toxicol., 2001, 89(5), 217-224.
48. Marchitti, S. A.; Deitrich, R. A.; Vasiliou, V. Neurotoxicity and metabolism of the catecholamine-derived 3, 4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde: The role of aldehyde dehydrogenase. Pharmacol. Rev., 2007, 59(2), 125-150.
49. Burke, W. J.; Kumar, V. B.; Pandey, N.; Panneton, W. M.; Gan, Q.; Franko, M. W.; O'Dell, M.; Li, S. W.; Pan, Y.; Chung, H. D.; Galvin, J. E. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol., 2008, 115(2), 193-203.
50. Mallajosyula, J. K.; Kaur, D.; Chinta, S. J.; Rajagopalan, S.; Rane, A.; Nicholls, D. G.; Di Monte, D. A.; Macarthur, H.; Andersen, J. K. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One, 2008, 3(2), e1616.
51. The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neurol., 1996, 40(1), 99-107.
52. Stocchi, F.; Vacca, L.; Grassini, P.; De Pandis, M. F.; Battaglia, G.; Cattaneo, C.; Fariello, R. G. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology, 2006, 67(7 Suppl 2), S24-29.
53. Schwartz, T. L. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr., 2013, 18(Suppl 1), 25-32.
54. Lum, C. T.; Stahl, S. M. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr., 2012, 17(3), 107-120.
55. Costa, F. H.; Rosso, A. L.; Maultasch, H.; Nicaretta, D. H.; Vincent, M. B. Depression in Parkinson's disease: diagnosis and treatment. Arq. Neuropsiquiatr., 2012, 70(8), 617-620.
56. Di Monte, D. A.; DeLanney, L. E.; Irwin, I.; Royland, J. E.; Chan, P.; Jakowec, M. W.; Langston, J. W. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of LDOPA-treated monkeys. Brain Res., 1996, 738(1), 53-59.
57. Da Prada, M.; Kettler, R.; Keller, H. H.; Burkard, W. P.; Haefely, W. E. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J. Neural Transm. Suppl., 1989, 28, 5-20.
58. Da Prada, M.; Zürcher, G.; Wüthrich, I.; Haefely, W. E. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm. Suppl., 1988, 26, 31-56.
59. Brown, C.; Taniguchi, G.; Yip, K. The monoamine oxidase inhibitor-tyramine interaction. J. Clin. Pharmacol., 1989, 29(6), 529-532.
60. Bonnet, U. Moclobemide: Therapeutic use and clinical studies. CNS Drug Rev., 2003, 9(1), 97-140.
61. Provost, J. C.; Funck-Brentano, C.; Rovei, V.; D'Estanque, J.; Ego, D.; Jaillon, P. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin. Pharmacol. Ther., 1992, 52(4), 384-393.
62. Vlok, N.; Malan, S. F.; Castagnoli, N. Jr.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg. Med. Chem., 2006, 14(10), 3512-3521.
63. Van den Berg, D.; Zoellner, K. R.; Ogunrombi, M. O.; Malan, S. F.; Terre'Blanche, G.; Castagnoli, N. Jr.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg. Med. Chem., 2007, 15(11), 3692-3702.
64. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D. E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem., 2007, 50(23), 5848-5852.
65. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P. A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43(25), 4747-4758.
66. Strydom, B.; Malan, S. F.; Castagnoli, N. Jr.; Bergh, J. J.; Petzer J, P. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg. Med. Chem., 2010, 18(3), 1018-1028.
67. Strydom, B.; Bergh, J. J.; Petzer, J. P. 8-Aryl-and alkyloxycaffeine analogues as inhibitors of monoamine oxidase. Eur. J. Med. Chem., 2011, 46(8), 3474-3485.
68. Strydom, B.; Bergh, J. J.; Petzer, J. P. The inhibition of monoamine oxidase by 8-(2-phenoxyethoxy)caffeine analogues. Arzneimittelforschung, 2012, 62(11), 513-518.
69. Okaecwe, T.; Swanepoel, A. J.; Petzer, A.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives. Bioorg. Med. Chem., 2012, 20(14), 4336-4347.
70. Booysen, H. P.; Moraal, C.; Terre'Blanche, G.; Petzer, A.; Bergh, J. J.; Petzer, J. P. Thio-and aminocaffeine analogues as inhibitors of human monoamine oxidase. Bioorg. Med. Chem., 2011, 19(24), 7507-7518.
71. Mostert, S.; Mentz, W.; Petzer, A.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues. Bioorg. Med. Chem., 2012, 20(24), 7040-7050.
72. Petzer, A.; Grobler, P.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues. J. Pharm. Pharmacol., 2014, 66(5). 677-687.
73. Son, S. Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2. 2-Å resolution: The control of opening the entry for substrates/inhibitors. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(15), 5739-5744.
74. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, D. E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol., 2002, 9(1), 22-26.
75. Walker, W. H.; Kearney, E. B.; Seng, R. L.; Singer, T. P. The covalently-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin. Eur. J. Biochem., 1971, 24(2), 328-331.
76. Kearney, E. B.; Salach, J. I.; Walker, W. H.; Seng, R. L.; Kenney, W.; Zeszotek, E.; Singer, T. P. The covalently-bound flavin of hepaticmonoamine oxidase. 1. Isolation and sequence of a flavin peptide and evidence for binding at the 8 position. Eur. J. Biochem., 1971, 24(2), 321-327.
77. Hubálek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D. E. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem., 2005, 280(16), 15761-15766.
78. Edmondson, D. E.; Binda, C.; Wang, J.; Upadhyay, A. K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry, 2009, 48(20), 4220-4230.
79. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P. A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem., 2006, 49(21), 6264-6272.
80. Youdim, M. B.; Weinstock, M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology, 2004, 25(1-2), 243-250.
81. Binda, C.; Hubálek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi, A. Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis. J. Med. Chem., 2005, 48(26), 8148-8154.
82. Gaspar, A.; Silva, T.; Yáñez, M.; Vina, D.; Orallo, F.; Ortuso, F.; Uriarte, E.; Alcaro, S.; Borges, F. Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J. Med. Chem., 2011, 54(14), 5165-5173.
83. Gaspar, A.; Reis, J.; Fonseca, A.; Milhazes, N.; Viña, D.; Uriarte, E.; Borges, F. Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(2), 707-709.
84. Krueger, M. J.; Mazouz, F.; Ramsay, R. R.; Milcent, R.; Singer, T. P. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun., 1995, 206(2), 556-562.
85. Mazouz, F.; Gueddari, S.; Burstein, C.; Mansuy, D.; Milcent, R. 5-4-(Benzyloxy)phenyl]-1, 3, 4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors. J. Med. Chem., 1993, 36(9), 1157-1167.
86. Shimada, J.; Koike, N.; Nonaka, H.; Shiozaki, S.; Yanagawa, K.; Kanda, T.; Kobayashi, H.; Ichimura, M.; Nakamura, J.; Kase, H.; Suzuki, F. Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg. Med. Chem. Lett., 1997, 18(7), 2349-2352.